Core Viewpoint - A securities fraud class action lawsuit has been filed against NuScale Power Corporation for misleading statements regarding its commercialization strategy and financial performance during a specific period [2][4][7]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased NuScale Class A common stock between May 13, 2025, and November 6, 2025 [2][7]. - The case is titled Truedson v. NuScale Power Corporation, et al, and is being heard in the United States District Court for the District of Oregon [2]. - Investors have until April 20, 2026, to file for lead plaintiff status [6][8]. Group 2: Allegations Against NuScale - The complaint alleges that NuScale made false and misleading statements about ENTRA1 Energy LLC's capabilities, claiming it had experience in nuclear power generation when it did not [4]. - It is claimed that NuScale's commercialization strategy was exposed to significant undisclosed risks due to reliance on ENTRA1, which lacked relevant experience [4]. - The lawsuit highlights that the financial mismanagement led to a dramatic increase in general and administrative expenses, which surged over 3,000% to $519 million in the third fiscal quarter [5]. Group 3: Financial Impact - Following the announcement of increased expenses, NuScale's quarterly net loss rose to $532 million, compared to $46 million in the prior year [5]. - The stock price of NuScale Class A common stock fell by $5.45 per share, approximately 14.4%, from $37.91 on November 5, 2025, to $32.46 on November 6, 2025 [5].

Core Viewpoint - Block & Leviton is investigating Camping World Holdings, Inc. for potential securities law violations following a significant drop in share price after the company announced a pause on its quarterly cash dividend [2][4]. Group 1: Company Actions - Camping World shares fell over 20% on February 25, 2026, due to the announcement of pausing its quarterly cash dividend to preserve capital allocation flexibility and prioritize debt reduction [2]. - The company cited reduced forecasted tax distributions as a reason for this decision, linked to recent tax law changes [2]. Group 2: Investor Information - Investors who have lost money on their Camping World investments may be eligible to recover losses and are encouraged to contact Block & Leviton for more information [3][5]. - The investigation by Block & Leviton aims to determine if Camping World committed any securities law violations that could affect investors [4]. Group 3: Whistleblower Program - Individuals with non-public information about Camping World are encouraged to assist in the investigation or report to the SEC under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Block & Leviton Overview - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - The lawsuit against BellRing Brands, Inc. alleges that the company and its executives misled investors regarding the true drivers of its sales growth, which was primarily due to retailers hoarding inventory rather than genuine consumer demand [3][5]. Company Overview - BellRing Brands, Inc. is facing a securities fraud lawsuit that claims misleading statements were made about the sustainability and drivers of its sales growth, as well as the competitive landscape affecting demand for its products [5][6]. Allegations of Misleading Information - The lawsuit contends that BellRing's reported sales growth in 2025 was artificially inflated due to retailers stockpiling inventory to mitigate previous supply chain issues, rather than reflecting actual consumer demand [3][7]. - A significant drop in BellRing's share price occurred after disclosures revealed that retailers were reducing their inventory levels, leading to a 33% decline in share price on August 4, 2025 [3][7]. Financial Impact - Following disappointing financial results for Q2 2025, BellRing's CFO acknowledged that some retailers had been hoarding inventory, which contributed to a 19% drop in share price [7]. - The Q3 2025 financial results further revealed a narrowed sales outlook, with the CFO attributing the disappointing performance to increased competition and a mismatch between consumption and shipments, resulting in a 33% drop in share price [7]. Investigation and Next Steps - Hagens Berman, the law firm leading the investigation, is actively seeking investors who purchased BellRing shares between November 19, 2024, and August 4, 2025, and suffered losses [6][8]. - The lead plaintiff deadline for the lawsuit is set for March 23, 2026 [6].

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against PayPal Holdings, Inc. (NASDAQ: PYPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired PayPal securities between February 25, 2025 and February 2, 2026, bo ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for securities fraud, alleging material misstatements regarding its Huntington's disease gene therapy drug, AMT-130, during the class period from September 24, 2025, to October 31, 2025 [1]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased uniQure ordinary shares during the specified class period [1]. - The deadline for investors to seek lead plaintiff status is April 13, 2026 [1]. Allegations - The key allegations include misleading statements about the Phase I/II clinical trials of AMT-130 and the timeline for the Biologics License Application (BLA) submission to the FDA [1]. - Specific misrepresentations include the lack of full FDA approval for the study design and the downplaying of the likelihood of delays in the BLA timeline due to additional studies required [1]. Impact on Share Price - On November 3, 2025, uniQure's share price dropped by $33.40, or over 49%, from $67.69 to $34.29, following revelations about the inadequacy of the data for BLA submission [1]. Investor Actions - Investors are encouraged to file for lead plaintiff status by the deadline or contact KTMC for a free case evaluation [1]. - The lead plaintiff will represent the class in directing the litigation and selecting counsel [1].

Core Company Overview - CoreWeave, Inc. is an AI cloud computing company based in Livingstone, NJ, providing advanced AI infrastructure and proprietary software [2]. Class Action Lawsuit - A class action lawsuit has been filed against CoreWeave on behalf of investors who acquired its securities between March 28, 2025, and December 15, 2025 [1]. - Investors have until March 13, 2026, to seek appointment as lead plaintiff representative of the class [2]. Financial Performance and Allegations - CoreWeave's shares were initially offered at $40 in March 2025 and peaked at $183.58 by June 20, 2025, with the company claiming "robust" and "unprecedented" demand for its offerings [3]. - The lawsuit alleges that CoreWeave misrepresented its ability to meet customer demand and downplayed risks associated with reliance on a single third-party data center provider [3]. - Significant investor losses occurred after the truth about these misrepresentations was revealed starting in October 2025 [3].

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP [Accessibility Statement] Skip NavigationDid you buy RARE common stock between August 3, 2023, and December 26, 2025?Affected Ultragenyx Pharmaceutical Inc. Investor Summary- Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)] for recovery options at no cost to investor- Key Lawsuit Allegations: Material misstatements and/or om ...

Boston, Massachusetts--(Newsfile Corp. - March 2, 2026) - Block & Leviton is investigating Tennant Company (NYSE: TNC) for potential securities law violations. Investors who have lost money in their Tennant Company investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/tnc.What is this all about?Shares of Tennant Company fell over 20% on February 24, 2026, after the company reported Q4 results that missed analyst ex ...

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased its American Depositary Shares during the specified class period, alleging misrepresentation of clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Mereo misrepresented the results of the ORBIT and COSMIC Phase 3 programs for setrusumab, a treatment for Osteogenesis Imperfecta [3]. - Investors were informed on December 29, 2025, that neither clinical trial met its primary endpoint, leading to a significant loss of over 87% in the value of Mereo's ADSs in one trading day [3]. Group 2: Company Background - Mereo BioPharma is a UK-based biopharmaceutical company focused on developing therapies for rare and serious conditions [2]. - The company is currently facing legal challenges that may impact its reputation and financial standing in the biopharmaceutical industry [1][3].

Core Viewpoint - A class action lawsuit has been filed against Enphase Energy, Inc. on behalf of investors who acquired its securities during the specified Class Period, alleging misleading statements and failure to disclose critical information regarding the company's financial and operational outlook [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Enphase overstated its ability to manage channel inventory levels and mitigate business impacts from the termination of the Residential Clean Energy Credit [3]. - The truth about Enphase's financial situation was revealed on October 28, 2025, when the company reported disappointing third-quarter results and warned of negative revenue impacts due to elevated channel inventory and lower battery storage shipments [4]. - Following the announcement, Enphase's stock price dropped by $5.56 per share, or 15.15%, closing at $31.14 on October 29, 2025 [5]. Group 2: Investor Information - Investors who purchased Enphase securities during the Class Period have until April 20, 2026, to seek appointment as lead plaintiff representatives [2].